RESEARCH & DEVELOPMENT
Phase I
DEX-TD is a transdermal formulation being developed for the adjunctive management of severe, intractable pain.This formulation is designed to deliver sustained plasma concentrations that would make this product a once to twice a day application.
January 2010:
DEX-TD Phase I Clinical
Study initiated.
December 2009:
William Ashton joins Board
of Directors.
September 2009:
DEX-SL Phase I Clinical Study initiated in the U.S.
